TMP-269 is an inhibitor of class II histone deacetylases (HDACs) that exhibits anticancer activity. In intestinal epithelial cells, TMP-269 inhibits cell cycle progression and cell proliferation. In multiple myeloma cells, this compound enhances carfilzomib-induced apoptosis.
| Cas No. | 1314890-29-3 |
|---|---|
| Purity | ≥98% |
| Formula | C25H21F3N4O3S |
| Formula Wt. | 514.52 |
| IUPAC Name | N-{[4-(4-Phenyl-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-yl]methyl}-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | T5060 Info Sheet PDF |
|---|
Kikuchi S, Suzuki R, Ohguchi H, et al. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015 Mar 24. [Epub ahead of print]. PMID: 25801913.
Sinnett-Smith J, Ni Y, Wang J, et al. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. Am J Physiol Cell Physiol. 2014 May 15;306(10):C961-71. PMID: 24647541.
